Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress

Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. As one of the long-standing academic meetings in the field of breast cancer, this year’s congress brought together leading Chinese and French experts in breast cancer treatment for live surgical demonstrations and in-depth discussions focused on oncoplastic breast-conserving surgery and breast reconstruction techniques.
2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy

2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy

From April 16–18, 2026, the 18th Northern Breast Cancer HOT Conference was successfully held in Henan Province. The meeting focused on cutting-edge advances and clinical challenges in breast cancer diagnosis and treatment, bringing together leading Chinese experts to explore new pathways toward standardized and individualized care.
ESMO BC 2026 | Academician Binghe Xu and Professor Jiayu Wang: Real-World Use of Adjuvant Abemaciclib in Chinese Patients With HR+/HER2− Early Breast Cancer

ESMO BC 2026 | Academician Binghe Xu and Professor Jiayu Wang: Real-World Use of Adjuvant Abemaciclib in Chinese Patients With HR+/HER2− Early Breast Cancer

Based on the results of the monarchE trial, abemaciclib combined with endocrine therapy (ET) has become the standard adjuvant treatment for patients with high-risk HR+/HER2− early breast cancer (EBC). However, systematic data regarding its use in routine Chinese clinical practice have remained limited.
CSCO BC 10th Anniversary Tribute · International Edition | Professor Zefei Jiang in Dialogue With Professor Michael Gnant: From SGBCC to CSCO BC—East-West Collaboration Shaping the Future of Breast Cancer Care

CSCO BC 10th Anniversary Tribute · International Edition | Professor Zefei Jiang in Dialogue With Professor Michael Gnant: From SGBCC to CSCO BC—East-West Collaboration Shaping the Future of Breast Cancer Care

During the 2026 National Breast Cancer Conference, Professor Michael Gnant, President of the St. Gallen International Breast Cancer Conference (SGBCC), traveled across continents to participate in the event, further deepening collaboration between SGBCC and the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC).
ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer

ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer

At the recently concluded ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Matteo Lambertini from IRCCS Ospedale Policlinico San Martino and the University of Genova served as one of the chairs of the session “Breast Cancer in Young Women (BCY) Session – Management of HR+ Breast Cancer in Young Women.” Together with fellow panelists, he participated in in-depth discussions on several key issues surrounding the management of breast cancer in young women.
ESMO BC Global Perspective | Professor Neelima Vidula: Pembrolizumab Plus Carboplatin Did Not Improve Disease Control in Advanced Breast Cancer With Chest Wall Disease, but the Search for Durable Responses Continues

ESMO BC Global Perspective | Professor Neelima Vidula: Pembrolizumab Plus Carboplatin Did Not Improve Disease Control in Advanced Breast Cancer With Chest Wall Disease, but the Search for Durable Responses Continues

At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Neelima Vidula from Massachusetts General Hospital presented the findings of the randomized phase II ICI-CHEST, TBCRC044 study (Abstract No. 425RO), offering important clinical insights into one of the most challenging settings in advanced breast cancer. The study investigated whether adding the PD-1 inhibitor pembrolizumab to standard carboplatin chemotherapy could improve outcomes in patients with advanced breast cancer accompanied by chest wall disease (CWD), a population known for extremely poor prognosis and limited responsiveness to systemic therapy.
ESMO BC Global Perspective | Professor Sung-Bae Kim: Rethinking Treatment for Intermediate-Risk HR+ Early Breast Cancer—Could Adjuvant CDK4/6 Inhibitors Replace Chemotherapy?

ESMO BC Global Perspective | Professor Sung-Bae Kim: Rethinking Treatment for Intermediate-Risk HR+ Early Breast Cancer—Could Adjuvant CDK4/6 Inhibitors Replace Chemotherapy?

During the “Adjuvant Therapy for Hormone Receptor-Positive Early Breast Cancer” session at the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Sung-Bae Kim from Asan Medical Center, University of Ulsan College of Medicine, delivered an insightful presentation entitled “Adjuvant CDK4/6 Inhibitors: Could They Replace Chemotherapy for Intermediate-Risk ER+ Early Breast Cancer?” Following the session, Professor Sung-Bae Kim spoke with Oncology Frontier and further elaborated on the key concepts presented in his talk.
Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Liquid biopsy technologies are rapidly advancing, and circulating tumor DNA (ctDNA) monitoring has demonstrated enormous potential in precision treatment for breast cancer. During the Educational Session “Adjuvant Therapy for ER-Positive Breast Cancer” at the ESMO Breast Cancer Congress (ESMO BC), Professor Heather Parsons from the Fred Hutchinson Cancer Center delivered a presentation entitled “The Role of ctDNA Monitoring in ER+ Early Breast Cancer: Could It Change Practice?”
Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou, Zhejiang Province. Hosted by the Second Affiliated Hospital of Zhejiang University School of Medicine, the event brought together top-tier colorectal surgery experts from across China for in-depth discussions on key topics, including colorectal cancer liver metastasis, peritoneal metastasis, para-aortic lymph node metastasis, locally advanced rectal cancer, combined organ resection, and the association between obesity and colorectal cancer. Prof. Toh Han Chong from the National Cancer Centre Singapore (NCCS) attended the conference.
Professor Qinlong Zheng: Focusing on Clonal Evolution to Optimize Hematologic Malignancy Diagnosis and Treatment

Professor Qinlong Zheng: Focusing on Clonal Evolution to Optimize Hematologic Malignancy Diagnosis and Treatment

To further advance scientific research and clinical practice in hematologic malignancies in China and establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical experience, and future directions in the discipline, creating a professional event with high academic value, strong clinical relevance, and broad industry influence.